If only anatomists were as familiar with the dissection of lower animals as with that of the human body, all these perplexing difficulties would, in my opinion
As noted by William Harvey over three and a half centuries ago, in vivo animal model systems are invaluable in clarifying the mechanisms of human disease. Although large animal models have long served as a gold standard, recent advances in transgenic and gene-targeting approaches, mouse genetics, and microsurgical technology are initiating a revolution in molecular medicine. Given the multifactorial, integrative, and acquired nature of the bulk of human diseases, the ability to fuse genetic-based approaches with the in vivo analysis of complex physiological traits is clearly one of the most important advances in the field of molecular medicine. In essence, the mouse now offers the genetic advantages of lower organisms, while having sufficient biological complexity to allow connections with human physiology and disease. To obtain a variety of viewpoints on future directions for Molecular Medicine in Genetically Engineered Animals , The Journal has commissioned a series of short perspectives from leaders in the field (see box below) which will run consecutively in issues of The Journal over the next several months. Of course, the use of the mouse as a model system for human physiology and disease is not without inherent difficulties. In fact, as the increasing resources developed by the Human Genome Project continue to accelerate the pace of the identification of genes potentially involved in health and disease, and as tools available for genome engineering gain even greater precision and sophistication, the need for combining molecular manipulation with precise physiological analysis will become critical for exploiting the full potential of the mouse.
For the past two decades, the intersection of genetics and human disease has been confined largely to the analysis of monogenic disease, which has provided a wealth of information on the molecular determinants of development, physiology, and disease. With the advent of the new mouse genetics and the development of miniaturized technology to rapidly and quantitatively assess in vivo physiological phenotypes, it is now possible to use genetic approaches to identify the molecular determinants of complex acquired diseases which form the bulk of human clinical disorders. Finding these target genes for complex diseases is likely to spawn a new era of molecular medicine, as well as a renaissance in in vivo physiology, that will be similar to the current impact of mouse genetics on the field of developmental biology. In the coming years, molecular biologists and clinicians are likely to be spending considerably more time at the bedside of mice which display interesting human disease phenotypes, perhaps giving new meaning to the following adage by Sir William Osler:
